YOLFTbeta
Aprogen Pharmaceuticals Inc

Aprogen Pharmaceuticals Inc

003060 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

1,307.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1,307.00
Open1,373.00
Day Range1,302.00 – 1,373.00
52-Week Range1,446.00 – 9,945.00
Volume37.14K
Market Cap25.17B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.21
50-Day Avg1,871.56
200-Day Avg3,979.45

About

Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jeong-Chool Kim
  • Employees262
  • Headquarters6, 31, Ogeum-ro 19-gil, Seoul, South Korea, Korea
  • Websitehttps://en.aprogen-pharm.com/index.do

Leadership

  • Mr. Jeong-Chool KimChief Executive Officer
  • Mr. Jung-Chul KimPresident

Financials

Income Statement

Currency: KRW2009-12-312010-09-302010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue62.23B58.65B16.69B50.12B33.77B29.54B33.09B40.32B44.12B46.10B45.40B50.90B53.32B56.48B65.19B87.36B67.38B73.23B
Growth (%)--5.74%-71.55%+200.33%-32.63%-12.52%+12.01%+21.85%+9.42%+4.48%-1.53%+12.13%+4.75%+5.93%+15.42%+34.01%-22.88%+8.68%
Cost of Revenue31.54B25.16B6.67B24.51B22.53B20.40B21.27B25.72B25.50B27.27B26.61B30.35B30.12B31.04B37.90B99.03B74.96B100.26B
Gross Profit-----8.16B10.50B14.60B18.63B18.83B18.78B20.56B23.20B25.44B27.29B-11.66B-7.58B-27.03B
Gross Margin-----27.63%31.74%36.21%42.21%40.85%41.37%40.39%43.51%45.05%41.86%-13.35%-11.25%-36.92%
Operating Expense-----23.85B16.15B15.47B18.87B20.29B19.61B22.49B24.17B29.24B30.76B46.13B45.74B33.45B
Operating Income3.99B4.60B1.27B1.01B--15.69B-5.65B-866.31M-247.37M-1.46B-825.59M-1.93B-972.30M-3.80B-3.48B-57.80B-53.31B-60.49B
Operating Margin6.41%7.84%7.60%2.02%--53.11%-17.07%-2.15%-0.56%-3.16%-1.82%-3.79%-1.82%-6.73%-5.33%-66.15%-79.13%-82.60%
EBITDA----------5.81B7.92B1.93B18.62B11.93B17.56B-88.32B-80.38B-139.49B
EBITDA Margin----------12.60%17.44%3.79%34.93%21.13%26.94%-101.09%-119.29%-190.50%
Net Income------20.85B-3.89B2.76B-3.92B-16.36B-1.22B-8.31B11.25B8.10B12.64B-118.27B-104.98B-170.33B
Net Income Margin------70.58%-11.75%6.85%-8.88%-35.50%-2.68%-16.33%21.10%14.35%19.39%-135.38%-155.81%-232.61%
R&D--321.71M491.06M-467.72M466.31M135.38M84.54M180.19M191.62M336.12M697.70M1.74B2.19B15.00B18.04B4.00B
R&D as % of Total Revenue--1.93%0.98%-1.58%1.41%0.34%0.19%0.39%0.42%0.66%1.31%3.07%3.35%17.17%26.77%5.47%
Interest Expense00000000007.40B3.33B49.06M31.14M274.41M3.67B5.51B10.70B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%16.31%6.53%0.09%0.06%0.42%4.20%8.18%14.61%

Balance Sheet

Currency: KRW2009-12-312010-09-302010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets59.07B67.64B78.70B116.33B93.08B78.26B84.83B85.22B128.69B158.27B217.06B365.28B615.31B614.62B684.14B589.40B590.98B586.99B
Total Liabilities33.89B26.26B35.89B42.85B24.58B21.71B22.71B17.48B50.57B80.41B66.55B17.65B16.95B17.44B173.73B220.71B212.29B309.43B
Total Equity25.01B41.38B42.81B73.49B68.51B56.25B62.33B69.23B80.40B77.86B150.51B246.34B505.39B507.94B426.52B368.69B378.49B207.76B
Cash2.97B3.72B2.25B12.77B14.20B17.97B9.33B17.93B26.22B23.78B21.63B30.30B64.80B35.07B23.61B10.05B12.31B24.39B
Net Debt---------27.87B16.38B---110.65B151.31B123.32B183.22B

Cash Flow

Currency: KRW2009-12-312010-09-302010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--247.92M---1.70B-6.92B1.85B449.98M-8.93B1.33B713.73M8.09B-6.23B25.73B-33.65B-31.00B-38.23B
Investing Cash Flow----9.75B1.72B-15.02B10.05B-35.53B-33.94B-58.11B-70.47B-195.27B-23.16B----
Financing Cash Flow31.11B6.39B8.40B33.57B-3.77B13.29B-3.30B43.37B40.46B54.61B78.44B221.70B-350.26M----
Capital Expenditure496.44M4.71B12.28B2.49B866.69M9.45B1.99B5.37B2.82B2.10B1.01B2.13B976.29M796.19M1.55B28.40B15.45B9.78B
Free Cash Flow----------11.58B-912.93M-1.71B6.67B-7.67B24.18B-62.05B-46.45B-48.01B
FCF to OCF---------129.67%-68.57%-239.21%82.43%123.16%93.99%184.38%149.85%125.58%

Earnings

Report DateMar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 12, 2021May 14, 2021Aug 13, 2021Nov 11, 2021Mar 14, 2022May 13, 2022Aug 12, 2022Nov 11, 2022Mar 17, 2023May 12, 2023Aug 14, 2023Nov 13, 2023Mar 14, 2024May 14, 2024Aug 14, 2024Nov 11, 2024Mar 12, 2025May 14, 2025Aug 12, 2025Nov 11, 2025Dec 31, 2025May 13, 2026Jun 30, 2026
EPS Estimate--------------------------------------------------------------
EPS Actual1211.88228.91-3833.42-7611.92-3864.65-25541.64-6713.31-13076.94-7285.13-3996.57-2050.30-8546.00-1447.15-606.17-1458.69-725.09-97.891699.19239.41804.85-11.33-139.39-671.71-2874.28-1931.26-3001.44-8989.88-1418.17-1698.071317.452790.65-3409.99-3561.58725.91-803.62-1214.691575.541779.872376.95-2.134.884.246.744.477.097.7611.22-4.361.91-28.14-7.39-147.22-71.68-345.65-90.77-303.71-217.72-338.57-123.37-2736.87-295.48-999.48
Surprise--------------------------------------------------------------
Timing-------------------------------------------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap25.17B
Enterprise Value211.64B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.29
Price / Book0.12
Revenue (TTM)86.18B
Gross Profit (TTM)-23.81B
EBITDA-78.50B
Profit Margin-90.85%
Operating Margin-58.24%
Return on Equity-23.95%
Return on Assets-10.66%
Shares Outstanding16.26M
Shares Float5.13M
Beta-0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 8, 20261:15
  • May 13, 20241333:1013
  • Apr 16, 20241:10
  • Jun 1, 20201066:939
  • Jun 19, 2019479:364
  • Aug 17, 20151:2
  • Jun 28, 20122:1
  • Mar 26, 20101115:1017
  • Mar 2, 20091:10
  • Sep 21, 200430:17